Table 4. Mean accumulated hospitalization time for cardiovascular and non-cardiovascular admissions, degree of CAD and sex in patients with angina compared to an asymptomatic reference population.
| Mean accumulated hospitalization time per 10 years of follow-up, days (95% confidence interval), age-adjusted to 60 years | |||||
| Women | Men | Pooled data | Pooled dataa | Pooled datab | |
| Study population group | n = 8,050 | n = 8,868 | n = 16,918 | n = 16,592 | n = 10,115 |
| CV hospitalization | |||||
| Reference | 2.8(2.1–3.5) | 3.9(3.1–4.7) | 3.2(2.7–3.7) | 3.5(3.0–4.0) | 3.3(2.8–3.8) |
| Angiographically normal | 3.5(2.9–4.2) | 7.7(6.1–9.3)* | 5.1(4.4–5.8)* | 4.5(3.8–5.2)§ | 3.9(3.0–4.7) |
| Angiographically diffuse | 7.6(4.5–10.8)$ | 8.6(6.5–10.7)* | 7.9(6.1–9.8)* | 7.0(5.4–8.6)* | 7.1(4.0–10.1)§ |
| 1VD | 6.7(5.2–8.1)* | 6.6(4.2–8.9)$ | |||
| 2VD | 6.1(4.9–7.4)* | 5.3(4.0–6.6)$ | |||
| 3VD | 8.6(6.6–10.7)* | 8.3(6.3–10.3)* | |||
| Non-CV hospitalization | |||||
| Reference | 16.6(15.2–18.1) | 21.3(18.6–24.1) | 18.9(17.5–20.4) | 22.3(20.1–24.4) | 22.1(19.9–24.2) |
| Angiographically normal | 16.2(14.3–18.1) | 25.2(21.0–29.5) | 20.1(18.0–22.1) | 20.6(18.3–22.8) | 23.8(19.7–27.9) |
| Angiographically diffuse | 25.8(15.8–35.8) | 25.9(20.5–31.3) | 25.8(20.2–31.3)§ | 21.1(17.4–24.8) | 22.0(15.6–28.4) |
| 1VD | 18.5(14.8–22.2) | 21.2(15.2–27.2) | 19.7(15.6–23.7) | 17.2(13.8–20.7)§ | 17.7(14.2–21.3)§ |
| 2VD | 18.8(10.6–26.9) | 20.0(15.7–24.2) | 18.8(15.0–22.7) | 18.0(14.0–22.0) | 17.6(11.9–23.3) |
| 3VD | 24.0(15.6–32.4) | 26.6(21.1–32.2) | 25.3(20.6–30.0)$ | 21.4(17.3–25.5) | 22.3(17.0–27.6) |
VD: vessel disease. CAD: coronary artery disease. CV: cardiovascular.
*P≤0.001; $P≤0.01; §P≤0.05 for difference compared with the reference population.
a
Limited to time from one year post-inclusion onwards.
b
Sensitivity analysis further limited to individuals with no diagnosis of aortic stenosis, atrial flutter, paroxysmal atrial fibrillation, hypertrophic cardiomyopathy, or perimyocarditis previously or within 6 months of inclusion and for the symptomatic population a left ventricular ejection fraction ≥40.